<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) accounts for the majority of childhood <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> seen in sub-Saharan Africa </plain></SENT>
<SENT sid="1" pm="."><plain>In Malawi, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CPM), the mainstay of treatment for endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, is effective in around 50% of cases </plain></SENT>
<SENT sid="2" pm="."><plain>Evidence exists in support of an association between activation of replication of Epstein-Barr virus (EBV) in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> and response to this chemotheraupeutic agent </plain></SENT>
<SENT sid="3" pm="."><plain>Phenylbutyrate (PB), approved for treatment of inborn errors of the <z:chebi fb="20" ids="16199">urea</z:chebi> cycle with minimal toxicity in children, induces EBV replication and cell lysis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-derived cell cultures </plain></SENT>
<SENT sid="4" pm="."><plain>It has also shown some success as adjuvant in treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>We tested in African <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> patients with CPM-resistant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, and thus unlikely to survive, the hypothesis that PB can reverse this resistance </plain></SENT>
<SENT sid="6" pm="."><plain>A study of five patients showed PB before CPM to induce shrinkage of CPM-resistant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> in two of them </plain></SENT>
<SENT sid="7" pm="."><plain>Findings suggested that for this effect PB pre-treatment should be given for a week before CPM treatment </plain></SENT>
<SENT sid="8" pm="."><plain>A larger study is indicated </plain></SENT>
</text></document>